What Is Aspirin?

Aspirin, chemically known as acetylsalicylic acid (ASA), is a small-molecule drug derived from salicylic acid that functions as an analgesic, antipyretic, anti-inflammatory, and antiplatelet agent. It is among the most widely used pharmaceutical compounds in clinical medicine, with applications ranging from acute pain and fever management to long-term cardiovascular prophylaxis. Bayer registered acetylsalicylic acid under the trade name aspirin in 1899, making it one of the earliest synthetically produced drugs to achieve global clinical adoption.

In the context of biomedical research and engineering, aspirin is studied for its established clinical roles and also as a reference compound in drug delivery research, biosensor development, and the broader pharmacological investigation of eicosanoid signaling pathways.

Mechanism of Action and COX Inhibition

Aspirin's primary pharmacological action is the irreversible inhibition of cyclooxygenase (COX) enzymes, specifically COX-1 and COX-2. These enzymes catalyze the first steps in the conversion of arachidonic acid to prostaglandins, prostacyclin, and thromboxane A2, lipid mediators that drive inflammation, pain, fever, and platelet aggregation. Aspirin acts by covalently acetylating a serine residue (Ser530) in the COX-1 active site and an analogous residue in COX-2, permanently blocking substrate access. The mechanism of action of aspirin was first elucidated by John Vane in 1971, work for which he shared the Nobel Prize in Physiology or Medicine in 1982. Because platelets lack nuclei and cannot synthesize new COX-1, a single aspirin dose produces antiplatelet effects that persist for the platelet's entire lifespan of seven to ten days.

Therapeutic Uses and Clinical Applications

At low doses (75 to 100 mg daily), aspirin's dominant effect is antiplatelet, reducing the risk of arterial thrombosis. It is prescribed for secondary prevention of myocardial infarction and ischemic stroke, and its use in acute ST-elevation myocardial infarction reduces mortality when given promptly. At higher doses (325 to 650 mg), anti-inflammatory and analgesic effects become clinically meaningful, applicable to headache, musculoskeletal pain, and fever. Clinical pharmacology and applications of aspirin also include its use in the prevention of pre-eclampsia in high-risk pregnancies, where its inhibition of thromboxane-mediated vasoconstriction is the proposed mechanism. Oncological research has observed associations between regular aspirin use and reduced incidence of colorectal and other cancers, though the mechanisms remain under investigation.

Pharmacokinetics and Formulation

Aspirin is rapidly absorbed in the stomach and upper small intestine, with peak plasma concentrations reached within 30 to 40 minutes of ingestion of non-enteric formulations. It undergoes hydrolysis to salicylate, which carries its own anti-inflammatory activity and has a longer half-life. At antiplatelet doses, aspirin itself is the active species; at higher doses, salicylate contributes substantially to the pharmacological effect. Enteric-coated formulations delay absorption to reduce gastric irritation, though evidence that they lower gastrointestinal bleeding risk is not conclusive. Aspirin serves frequently in pharmaceutical engineering research as a model hydrophilic drug for testing controlled-release polymer matrices, nanoparticle carriers, and transdermal delivery systems. The StatPearls review of salicylic acid pharmacology provides a detailed overview of absorption, distribution, metabolism, and excretion characteristics used as benchmarks in formulation studies.

Applications

Aspirin and acetylsalicylic acid chemistry have applications across a range of research and clinical fields, including:

• Cardiovascular medicine and antiplatelet therapy protocols
• Anti-inflammatory and analgesic drug design
• Drug delivery research using aspirin as a model compound for polymer matrix systems
• Biosensor development for aspirin detection and pharmacokinetic monitoring
• Cancer chemoprevention research, particularly in colorectal oncology
• Obstetric medicine and pre-eclampsia risk reduction